204
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Study of a novel disintegrable oleanolic acid-polyvinylpolypyrrolidone solid dispersion

, , , &
Pages 1178-1185 | Received 22 Oct 2016, Accepted 27 Feb 2017, Published online: 16 Mar 2017

References

  • Jia XI, Tang HY, Zheng Y. Oral dosage forms of oleanolic acid and their pharmacokinetics. Chin J New Drugs 2009;18:507–15.
  • Song M, Hang TJ, Wang Y, et al. Determination of oleanolic acid in human plasma and study of its pharmacokinetics in Chinese healthy male volunteers by hplc tandem mass spectrometry. J Pharma Biomed Analysis 2006;40:190–6.
  • Wang X, Li YL, Wu H, et al. Antidiabetic effect of oleanolic acid: a promising use of a traditional pharmacological agent. Phytotherapy Res Ptr 2011;25:1031–40.
  • Tong HHY, Du Z, Wang GN, et al. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS class IV compound. Int J Pharma 2011;404:148–58.
  • Pollier J, Goossens A. Oleanolic acid. Phytochemistry 2012;77:10–15.
  • Man DKW, Casettari L, Cespi M, et al. Oleanolic acid-loaded pegylated pla and plga nanoparticles with enhanced cytotoxic activity against cancer cells. Mol Pharma 2015;12: 2112–25.
  • Alvarado HL, Abrego G, Garduño-Ramirez ML, et al. Design and optimization of oleanolic/ursolic acid-loaded nanoplatforms for ocular anti-inflammatory applications. Nanomedicine Nanotechnol Biol Med 2015;11:521–30.
  • Afifi S. Solid dispersion approach improving dissolution rate of stiripentol: a novel antiepileptic drug. Iran J Pharma Res 2015;14:1001–14.
  • Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharma Biopharma 2000;50:47–60.
  • Sjökvist E, Nyström C, Aldén M, et al. Physicochemical aspects of drug release. XIV: the effects of some ionic and non-ionic surfactants on properties of a sparingly soluble drug in solid dispersions. Int J Pharma 1992;79:123–33.
  • Itai S, Nemoto M, Kouchiwa S, et al. Influence of wetting factors on the dissolution behavior of flufenamic acid. Chem Pharm Bull 1986;33:5464–73.
  • Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharma 2004;282:151–62.
  • Dannenfelser RM, He H, Joshi Y, et al. Development of clinical dosage forms for a poorly water soluble drug. I: application of polyethylene glycol–polysorbate 80 solid dispersion carrier system. J Pharma Sci 2004;93:1165–75.
  • Qian F, Wang J, Hartley R, et al. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Pharma Res 2012;29:2765–76.
  • Yadav PS, Kumar V, Singh UP, et al. Physicochemical characterization and in vitro, dissolution studies of solid dispersions of ketoprofen with pvp k30 and d -mannitol. Saudi Pharma J 2013;21:77–84.
  • Vigh T, Balázs D, Attila B, et al. Oral bioavailability enhancement of flubendazole by developing nanofibrous solid dosage forms. Drug Dev Ind Pharm 2017. [Epub ahead of print]. https://doi.org/10.1080/03639045.2017.1298121.
  • Kumar S, Mishra DN, Singh SK. Enhancement of dissolution and bioavailability of fenofibrate by solid dispersion with sodium citrate, HPMC and sugar derivatives. Der Pharmacia Lettre 2015;7:162–73.
  • Tsunashima D, Yamashita K, Ogawara KI, et al. Preparation of extended release solid dispersion formulations of tacrolimus using ethylcellulose and hydroxypropylmethylcellulose by solvent evaporation method. J Pharm Pharmacol 2016;68:316–23.
  • Nguyen NG, Tran HL, Vo TV, et al. Dissolution enhancement of curcumin by solid dispersion with polyethylene glycol 6000 and hydroxypropyl methylcellulose. IFMBE Proc 2015;46:298–301.
  • Rawlinson CF, Williams AC, Timmins P, et al. Polymer-mediated disruption of drug crystallinity. Int J Pharma 2007;336:42–8.
  • Démuth B, Nagy ZK, Balogh A, et al. Down stream processing of polymer-based amorphous solid dispersions to generate tablet formulations. Int J Pharma 2015;486:268–86.
  • Zhang ZH, Su Xin L, Hui Xia L. Solidification of volatile oil of cinnamomum cassia with polyvinylpolypyrrolidone. Chin Pharma J 2014; 49:1913–16.
  • Fujii M, Okada H, Shibata Y, et al. Preparation, characterization, and tableting of a solid dispersion of indomethacin with crospovidone. Int J Pharma 2005;293:145–53.
  • Shibata Y, Fujii M, Kokudai M, et al. Effect of characteristics of compounds on maintenance of an amorphous state in solid dispersion with crospovidone. J Pharma Sci 2007;96:1537–47.
  • Lin SP, Hou YC, Liao TY, et al. Enhancing the bioavailability of magnolol in rabbits using melting solid dispersion with polyvinylpyrrolidone. Drug Dev Ind Pharm 2014;40:330–7.
  • Malamatari M, Somavarapu S, Bloxham M, et al. Nanoparticle agglomerates of indomethacin: the role of poloxamers and matrix former on their dissolution and aerosolisation efficiency. Int J Pharma 2015;495:516–26.
  • Kasperek R, Galczynski K, Nalesniak M, et al. Influence of the dissolution medium on the release of dehydroepiandrosterone from lipophilic suppositories. Curr Issues Pharm Med Sci 2014;27:46–50.
  • Liu C, Liu C, Desai KG. Enhancement of dissolution rate of valdecoxib using solid dispersions with polyethylene glycol 4000. Drug Dev Ind Pharm 2005;31:1–10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.